AVI BioPharma Inc. (AVII) News

News for AVI BioPharma Inc. (AVII)

Sector News | Topic News

After Hours: $ 1.08

-0.03 (-2.70%)

Volume: 900

4:00 PM EST Feb 10, 2012

Thu, Feb 09, 2012

8:30 AM

Results From Phase I Clinical Trials Demonstrate Positive Safety Data of AVI BioPharma's RNA-Based Therapeutics for Treatment of Ebola and Marburg Viruses - Marketwire

Thu, Feb 02, 2012

8:30 AM

AVI BioPharma to Present Company Overview at the 14th Annual BIO CEO & Investor Conference - Marketwire

Wed, Jan 04, 2012

9:00 AM

AVI BioPharma Data Safety Monitoring Board Reports No Safety Concerns Identified in Phase IIb DMD Clinical Trial, Recommends Continuation of Trial - Marketwire

Wed, Dec 14, 2011

5:10 PM

AVI BioPharma Receives NASDAQ Notice of Minimum Bid Price Non-Compliance - Marketwire

Fri, Dec 09, 2011

9:00 AM

AVI BioPharma Names Jayant Aphale, Ph.D., Senior Vice President of Technical Operations - Marketwire

Tue, Nov 22, 2011

5:00 PM

AVI BioPharma to Present Company Overview at the Piper Jaffray Health Care Conference - Marketwire

Tue, Nov 15, 2011

8:00 AM

AVI Enters Into Collaborations for the Development of Two Additional Exon-Skipping Products for Duchenne Muscular Dystrophy (DMD) - Marketwire

Tue, Nov 08, 2011

8:01 AM

AVI BioPharma to Present Company Overview at the Lazard Capital Markets 8th Annual Healthcare Conference - Marketwire

Thu, Nov 03, 2011

4:05 PM

AVI BioPharma Announces Third Quarter 2011 Financial Results and Recent Corporate Developments - Marketwire

Wed, Oct 26, 2011

8:00 AM

AVI BioPharma Announces Third Quarter 2011 Financial Results and Corporate Update Conference Call - Marketwire

Fri, Oct 21, 2011

8:16 AM

Volatility Grows in Biotech Sector -- Keryx and AVI BioPharma Need to Put Up Results - Marketwire

8:00 AM

AVI BioPharma's RNA-Based Therapeutics for Treatment of Ebola and Marburg Viruses Show Positive Safety Data in First Five of Six Cohorts of Phase 1 Clinical Studies - Marketwire

Tue, Oct 18, 2011

8:00 AM

AVI BioPharma Announces Data Presentation for RNA-Based Duchenne Muscular Dystrophy Drug Candidate at the 16th International World Muscle Society Congress - Marketwire

Mon, Sep 19, 2011

8:00 AM

AVI BioPharma Announces Presentations at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting - Marketwire

Wed, Sep 14, 2011

8:00 AM

AVI BioPharma to Present Company Overview at the UBS Global Life Sciences Conference - Marketwire

Tue, Sep 06, 2011

8:16 AM

AEterna Zentaris and AVI BioPharma Maintain Steady Pipelines - Marketwire

Thu, Sep 01, 2011

8:00 AM

AVI BioPharma to Present Company Overview at the Stifel Nicolaus 2011 Healthcare Conference - Marketwire

Mon, Aug 15, 2011

4:05 PM

AVI BioPharma Initiates Dosing in Phase 2 Study of Eteplirsen in Duchenne Muscular Dystrophy Patients - Marketwire

Wed, Aug 10, 2011

8:00 AM

AVI BioPharma to Present Company Overview at the Wedbush Securities Life Science Conference - Marketwire

Thu, Aug 04, 2011

4:00 PM

AVI BioPharma Announces Second Quarter 2011 Financial Results and Recent Corporate Developments - Marketwire

Thu, Jul 28, 2011

8:00 AM

AVI BioPharma Announces Second Quarter 2011 Financial Results and Corporate Update Conference Call - Marketwire

Mon, Jul 25, 2011

7:00 AM

The Lancet Publishes Clinical Trial Data That Demonstrate Statistically Significant and Dose-Dependent Expression of Dystrophin in Duchenne Muscular Dystrophy Patients Treated With AVI BioPharma's Eteplirsen - Marketwire

Tue, Jul 19, 2011

8:16 AM

Developmental Drugs Draw Scrutiny From FDA - Marketwire

Tue, Jun 21, 2011

8:00 AM

AVI BioPharma Expands Clinical Pipeline With Initiation of Phase 1 Study of Influenza Therapeutic Candidate - Marketwire

Thu, Jun 16, 2011

8:00 AM

AVI BioPharma and Naval Medical Research Center Successfully Complete Simultaneous Rapid-Response Exercises Against Bacterial and Viral Threats in 18 Days - Marketwire

First

1 2

Last